RESUMEN
Background: The utility of large language model-based (LLM) artificial intelligence (AI) chatbots in many aspects of healthcare is becoming apparent though their ability to address patient concerns remains unknown. We sought to evaluate the performance of two well-known, freely-accessible chatbots, ChatGPT and Google Bard, in responding to common questions about stroke rehabilitation posed by patients and their caregivers. Methods: We collected questions from outpatients and their caregivers through a survey, categorised them by theme, and created representative questions to be posed to both chatbots. We then evaluated the chatbots' responses based on accuracy, safety, relevance, and readability. Interrater agreement was also tracked. Results: Although both chatbots achieved similar overall scores, Google Bard performed slightly better in relevance and safety. Both provided readable responses with some general accuracy, but struggled with hallucinated responses, were often not specific, and lacked awareness of the possibility for emotional situations with the potential to turn dangerous. Additionally, interrater agreement was low, highlighting the variability in physician acceptance of their responses. Conclusions: AI chatbots show potential in patient-facing support roles, but issues remain regarding safety, accuracy, and relevance. Future chatbots should address these problems to ensure that they can reliably and independently manage the concerns and questions of stroke patients and their caregivers.
RESUMEN
BACKGROUND: Biodegradable polymer drug eluting stents (BP-DES) may offer the advantage of vascular healing in ST-segment elevation myocardial infarction (STEMI). Long-term outcome data comparing BP-DES and second-generation durable polymer drug eluting stents (DP-DES) in STEMI is lacking. This study aims to compare the long-term clinical outcomes of BP-DES versus second-generation DP-DES in STEMI. METHODS: This is an observational study of consecutive patients with STEMI who received either BP-DES (n = 854) or DP-DES (n = 708) during primary percutaneous coronary intervention (PCI) from 1st February 2007 to 31st December 2016. The primary outcome was target lesion failure (TLF), a composite of cardiac death, target vessel myocardial infarction (MI), and target lesion revascularization with follow up till 30th November 2019. RESULTS: The baseline demographics, lesion and procedural characteristic were similar between the two groups except for more prior MI and chronic obstructive pulmonary disease in the BP-DES group. At a median follow up of 4.2 years (interquartile range: 2.6-6.2 years), the incidence of TLF was similar between BP-DES and DP-DES (adjusted hazard ratio [HR] 0.94, 95% confidence interval [CI] 0.70-1.26). Likewise, incidence of major adverse cardiovascular events (MACE: all-cause death, any MI or target vessel revascularization) and definite stent thrombosis were similar in both groups (MACE: adjusted HR 1.04, 95% CI 0.82-1.32; definite stent thrombosis: adjusted HR 1.06, 95% CI 0.31-3.64). CONCLUSION: Among patients with STEMI who underwent primary PCI, BP-DES and DP-DES implantation was associated with similar long-term clinical outcomes.